Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You read people touting a move to a US listing as the solution to all problems. Liquidity is better and there is multiple expansion. The multiple expansion will come and bite where it hurts when the inevitable contraction happens and the liquidity acts in both directions.
Better for TRX to stay where it is and wait and let it work itself out and for the patient to buy at bargain prices.
Totally understandable, but I would sit tight. The company is doing well. I think we all recognise that the suitability of the aim will be under review, and a Nasdaq listing (either joint or as an alternative) seems obvious once appropriate. It is operationally a US company after all. A takeover or being taken private (with a view to a US listing) are other potentials. Being taken private or sole Nasdaq listing has obvious drawbacks for uk PIs re ISAs
I have sold on third of my holding here. After three years I still showed a small loss but the market shows no interest in this company. I fear it might move to America before some large pharma snaps it up.
Risk adversion is becoming dire..... I still have the other two thirds because I can see nothing better to buy! I really hope something changes.
Yes markets in the doldrums - in other times the growth story here would have been richly rewarded. IMO it will happen soon enough - maybe a move from aim to nasdaq? The fact they can’t raise prices shows how competitive their market is so surely their being bought with less resulting less competition/economy of scale makes sense?
118 shares traded today in TRX , says it all really. Hopefully a takeover will be in the offing .
Before anyone says , I'm not suggesting we are listed on the FTSE ,AIM is worse!
The UK market is an ass, that's why many companies are leaving the UK. The FTSE doesn't even track the Dow now like it used to in the 90's. The FTSE is way below the valuation of the Dow.
The only time TRX will be valued correctly is if a takeover happens , otherwise UK hasn't a clue how to value anything.
I think that is the key point - I thought for many years they would have to raise again when they expanded and they have now ruled that out. Not only is that almost unique in an AIM share it also confirms management's confidence in themselves, their employees and the business
The report suggests that we are well undervalued ... well done Sherlock
Sorry, the No was about the £4 exit strategy
No
For three years I have held this share. So far I have nothing to show. The sp is moribund. However I do believe that the sun will come out tomorrow.... Its just a matter of living long enough to enjoy it. Talk over 2 pounds or four is just idle dreaming...Sometimes though dreams come true
I think most holders here would be delighted with a £2 share price even if that takes 2, 3, 4 years?
20% continual growth in revenues will make biotech funds sit up and take notice, just need one/two to start nibbling away at the shares for momentum to build.
Just glad we don't need to raise equity as numerous companies in the sector are having to take big haircuts on SP or choosing to delist entirely.
£4 exit strategy in 2 years? Is that what they've said? Not wanting to be confrontational, I haven't done much reading up on here, just genuinely curious :-)
The Board and the nature of the institutional investors know the value of what is being created. £4 exit strategy in 2years.
The Hardman report suggests a fair value of £1.77 per share!
A bit of a hidden gem this one. Have high hopes for this and hVIVO after getting my backside kicked with DeepVerge. Been here a long time and happy to wait a bit longer!!
Sadly not a lot of interest.
Poetically put and totally agree
Like a fine bottle of Champagne, the cork is being eased out and when it’s ready it will pop. All the right things being done by management, institutions seeing the value which only reduces the free float meaning when this company’s value is realised it will fly.
Founded in 1796, Lombard Odier is the oldest private bank in Geneva and one of the largest in Switzerland and in Europe ... sounds good to me. LH&K Mafuta
Good to see Lombard Odier steadily increasing their stake: 10.01% last year, 10.75% in February, now 11.03%
Were they a buy at 73?
I haven't sold any , I thought I made my stance clear?
This time the top was 73 , it was pretty obvious even to a fool like me.
If you couldn't see that then don't ask.
Just now, I'd rate them a buy. It's a very thinly traded stock, and the share price always drops after results as the short term traders unload their speculative holdings. It'll drift up again in the coming months to a new high prior to the next trading update in July. Thereafter, falling back again - unless, of course, there's some really good news in the update, in which case you'd kick yourself for having sold too early :-)
If you do spot a high again, please let us all know before it passes ;-)